# Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Study · id `cardio:ct-nct01620489` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01620489](<https://clinicaltrials.gov/study/NCT01620489>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01620489

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.

## Technical summary

Registry record NCT01620489. Randomized; double masking; primary purpose treatment. Start 2012-06-14 (actual); primary completion 2013-08-20 (actual). Results posted on 2014-10-30.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 279 participants (enrolled count; ClinicalTrials.gov record NCT01620489, source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)
- Started: 2012-06-14 (actual) (ClinicalTrials.gov record NCT01620489, source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)
- Primary completion: 2013-08-20 (actual) (ClinicalTrials.gov record NCT01620489, source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)
- Completion: 2013-08-20 (actual) (ClinicalTrials.gov record NCT01620489, source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)
- Results first posted: 2014-10-30 (ClinicalTrials.gov record NCT01620489, source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)
- Countries: United States; France; Poland; Russia; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01620489, source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01620489-2019-03-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): liraglutide
- Intervention (Drug): placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial (`cardio:pubmed-26681713`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment (`cardio:pubmed-30663196`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes (`cardio:pubmed-29729957`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fe94ffd94992ee9244361045f5b13777d6d25b82a3b0cbfcca9a1ec10ac55a52
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
